Award

2019YFE0123700

Funder: National Key Research and Development Program of China

Funded outputs count: 8

Funder award ID: 2019YFE0123700

OpenAlex ID: G426577572

Key imidazolyl groups that induce phenylalanine flipping enhance the efficacy of oral BRD9 inhibitors for AML treatment

2025 · Zhiming Chen, Cheng Zhang, et al. · Acta Pharmaceutica Sinica B · 4

Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer

2025 · Hui Shen, Hongrui Xu, et al. · Journal of Medicinal Chemistry · 13

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

2024 · Tianbang Wu, Jiankang Hu, et al. · Journal of Medicinal Chemistry · 13

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

2024 · Jiankang Hu, Hongrui Xu, et al. · Journal of Medicinal Chemistry · 25

1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells

2024 · Shiting Zhao, Abdelsalam S. Ali, et al. · Bioorganic & Medicinal Chemistry · 3

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia

2024 · Wenhua Jiang, Qiangqiang Hou, et al. · Journal of Medicinal Chemistry · 29

Optimization of the synthesis of BET BD2 selective inhibitor XY153

2024 · Run Zhu, Junhua Li, et al. · Chemistry & Biodiversity · 2

Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer

2023 · Junhua Li, Run Zhu, et al. · Bioorganic Chemistry · 4